S&P 500   3,322.25 (+0.02%)
DOW   29,158.20 (-0.10%)
QQQ   224.24 (+0.17%)
AAPL   318.81 (+0.35%)
FB   220.33 (-0.45%)
MSFT   166.11 (+0.25%)
GOOGL   1,487.49 (+0.22%)
AMZN   1,885.56 (-0.10%)
CGC   24.17 (+0.21%)
NVDA   252.44 (+0.96%)
BABA   219.11 (-1.47%)
MU   59.19 (+0.03%)
GE   11.79 (+3.69%)
TSLA   568.64 (-0.16%)
AMD   51.60 (+0.31%)
T   38.69 (-0.90%)
ACB   2.03 (-0.98%)
F   9.11 (-0.55%)
NFLX   342.53 (+5.07%)
PRI   125.88 (-0.62%)
BAC   34.21 (-0.44%)
DIS   142.17 (-1.28%)
GILD   63.88 (+0.71%)
S&P 500   3,322.25 (+0.02%)
DOW   29,158.20 (-0.10%)
QQQ   224.24 (+0.17%)
AAPL   318.81 (+0.35%)
FB   220.33 (-0.45%)
MSFT   166.11 (+0.25%)
GOOGL   1,487.49 (+0.22%)
AMZN   1,885.56 (-0.10%)
CGC   24.17 (+0.21%)
NVDA   252.44 (+0.96%)
BABA   219.11 (-1.47%)
MU   59.19 (+0.03%)
GE   11.79 (+3.69%)
TSLA   568.64 (-0.16%)
AMD   51.60 (+0.31%)
T   38.69 (-0.90%)
ACB   2.03 (-0.98%)
F   9.11 (-0.55%)
NFLX   342.53 (+5.07%)
PRI   125.88 (-0.62%)
BAC   34.21 (-0.44%)
DIS   142.17 (-1.28%)
GILD   63.88 (+0.71%)
S&P 500   3,322.25 (+0.02%)
DOW   29,158.20 (-0.10%)
QQQ   224.24 (+0.17%)
AAPL   318.81 (+0.35%)
FB   220.33 (-0.45%)
MSFT   166.11 (+0.25%)
GOOGL   1,487.49 (+0.22%)
AMZN   1,885.56 (-0.10%)
CGC   24.17 (+0.21%)
NVDA   252.44 (+0.96%)
BABA   219.11 (-1.47%)
MU   59.19 (+0.03%)
GE   11.79 (+3.69%)
TSLA   568.64 (-0.16%)
AMD   51.60 (+0.31%)
T   38.69 (-0.90%)
ACB   2.03 (-0.98%)
F   9.11 (-0.55%)
NFLX   342.53 (+5.07%)
PRI   125.88 (-0.62%)
BAC   34.21 (-0.44%)
DIS   142.17 (-1.28%)
GILD   63.88 (+0.71%)
S&P 500   3,322.25 (+0.02%)
DOW   29,158.20 (-0.10%)
QQQ   224.24 (+0.17%)
AAPL   318.81 (+0.35%)
FB   220.33 (-0.45%)
MSFT   166.11 (+0.25%)
GOOGL   1,487.49 (+0.22%)
AMZN   1,885.56 (-0.10%)
CGC   24.17 (+0.21%)
NVDA   252.44 (+0.96%)
BABA   219.11 (-1.47%)
MU   59.19 (+0.03%)
GE   11.79 (+3.69%)
TSLA   568.64 (-0.16%)
AMD   51.60 (+0.31%)
T   38.69 (-0.90%)
ACB   2.03 (-0.98%)
F   9.11 (-0.55%)
NFLX   342.53 (+5.07%)
PRI   125.88 (-0.62%)
BAC   34.21 (-0.44%)
DIS   142.17 (-1.28%)
GILD   63.88 (+0.71%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NYSE:XYL - Xylem Stock Price, Forecast & News

$82.11
+0.09 (+0.11 %)
(As of 01/23/2020 02:56 PM ET)
Today's Range
$81.35
Now: $82.11
$82.18
50-Day Range
$74.91
MA: $79.11
$83.46
52-Week Range
$67.71
Now: $82.11
$85.67
Volume52,528 shs
Average Volume768,753 shs
Market Capitalization$14.79 billion
P/E Ratio29.33
Dividend Yield1.16%
Beta1.16
Xylem Inc engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation and treatment of water. Read More…

Industry, Sector and Symbol

Industry Pumps & pumping equipment
Sub-IndustryIndustrial Machinery
SectorIndustrial Products
CUSIP98419M10
Phone914-323-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.21 billion
Cash Flow$4.34 per share
Book Value$15.48 per share

Profitability

Net Income$549 million

Miscellaneous

Employees17,000
Market Cap$14.79 billion
Next Earnings Date2/6/2020 (Confirmed)
OptionableOptionable

Receive XYL News and Ratings via Email

Sign-up to receive the latest news and ratings for XYL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Xylem (NYSE:XYL) Frequently Asked Questions

What is Xylem's stock symbol?

Xylem trades on the New York Stock Exchange (NYSE) under the ticker symbol "XYL."

How often does Xylem pay dividends? What is the dividend yield for Xylem?

Xylem declared a quarterly dividend on Thursday, October 17th. Investors of record on Thursday, October 31st will be given a dividend of $0.24 per share on Thursday, December 5th. This represents a $0.96 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Wednesday, October 30th. View Xylem's Dividend History.

How were Xylem's earnings last quarter?

Xylem Inc (NYSE:XYL) posted its quarterly earnings data on Thursday, October, 31st. The industrial products company reported $0.82 EPS for the quarter, meeting the consensus estimate of $0.82. The industrial products company earned $1.30 billion during the quarter, compared to the consensus estimate of $1.33 billion. Xylem had a return on equity of 19.14% and a net margin of 9.65%. The company's revenue was up .7% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 EPS. View Xylem's Earnings History.

When is Xylem's next earnings date?

Xylem is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Xylem.

What guidance has Xylem issued on next quarter's earnings?

Xylem issued an update on its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $3.01-3.03 for the period, compared to the Thomson Reuters consensus estimate of $3.16. The company issued revenue guidance of $5.24-5.27 billion, compared to the consensus revenue estimate of $5.36 billion.

What price target have analysts set for XYL?

12 equities research analysts have issued 1 year price objectives for Xylem's shares. Their forecasts range from $70.00 to $89.00. On average, they expect Xylem's share price to reach $81.11 in the next year. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for Xylem.

What is the consensus analysts' recommendation for Xylem?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xylem in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xylem.

What are Wall Street analysts saying about Xylem stock?

Here are some recent quotes from research analysts about Xylem stock:
  • 1. According to Zacks Investment Research, "Xylem believes that solid sales in utilities and commercial end markets will aid top-line performance in the quarters ahead. Also, solid contract wins and healthy backlog will be beneficial. Further, its policy of rewarding shareholders handsomely through dividend payments and share buyback adds to its competitive appeal. However, the company expects to witness headwinds in residential and industrial end markets. For 2019, it lowered revenue projection from the earlier $5.3-$5.4 billion to $5.29-$5.38 billion. Also, adjusted earnings per share are predicted to be $3.12-$3.22 compared with $3.12-$3.32 mentioned earlier. In addition, high debts, forex woes and weak margins might be detrimental for Xylem. In the past three months, the company's shares have underperformed the industry and also look comparatively overvalued." (10/14/2019)
  • 2. Boenning Scattergood analysts commented, "We met with Xylem sales and engineering staff this week at a significant industry event for the analytics platform within the company’s Measurement & Control Solutions business. Overall, the discussions affirmed our positive thesis on the stock, with the show highlighting Xylem’s unique combination of best-in-class commercial execution, robust innovation pipeline, and attractive underlying markets. The 2020 margin target has been a focus for investors, but we believe improved profitability in the MCS segment will enable Xylem to approach the low end, and the Pittcon feedback affirms this view. Our $92 target (up from $82) reflects a forward P/E of 24 times, in-line with the water infrastructure peer group average." (3/22/2019)

Has Xylem been receiving favorable news coverage?

Press coverage about XYL stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xylem earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news stories about the industrial products company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Xylem.

Who are some of Xylem's key competitors?

What other stocks do shareholders of Xylem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xylem investors own include AT&T (T), Verizon Communications (VZ), NVIDIA (NVDA), Cisco Systems (CSCO), Intel (INTC), Walt Disney (DIS), Exxon Mobil (XOM), Alibaba Group (BABA), Pfizer (PFE) and Micron Technology (MU).

Who are Xylem's key executives?

Xylem's management team includes the folowing people:
  • Mr. Patrick K. Decker, Pres, CEO & Director (Age 54)
  • Mr. E. Mark Rajkowski, Sr. VP & CFO (Age 60)
  • Ms. Claudia S. Toussaint, Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Colin R. Sabol, Sr. VP and Pres of Measurement & Control Solutions (Age 51)
  • Mr. Kenneth Napolitano, Sr. VP and Pres of Applied Water Systems & Americas Commercial Team (Age 57)

Who are Xylem's major shareholders?

Xylem's stock is owned by many different of retail and institutional investors. Top institutional investors include DAVENPORT & Co LLC (0.30%), Candriam Luxembourg S.C.A. (0.29%), Mountain Pacific Investment Advisers Inc. ID (0.26%), Scout Investments Inc. (0.24%), Hexavest Inc. (0.21%) and Zurcher Kantonalbank Zurich Cantonalbank (0.20%). Company insiders that own Xylem stock include Claudia S Toussaint, Colin R Sabol, Curtis J Crawford, Kairus Tarapore, Kenneth Napolitano, Markos I Tambakeras, Pak Steven Leung, Paul A Stellato, Steven R Loranger and Tomas Brannemo. View Institutional Ownership Trends for Xylem.

Which major investors are selling Xylem stock?

XYL stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Scout Investments Inc., State of Alaska Department of Revenue, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Boenning & Scattergood Inc., Independent Investors Inc., Private Asset Management Inc. and Donaldson Capital Management LLC. Company insiders that have sold Xylem company stock in the last year include Claudia S Toussaint, Colin R Sabol, Curtis J Crawford, Kenneth Napolitano, Markos I Tambakeras, Pak Steven Leung, Steven R Loranger and Tomas Brannemo. View Insider Buying and Selling for Xylem.

Which major investors are buying Xylem stock?

XYL stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., DAVENPORT & Co LLC, Candriam Luxembourg S.C.A., Ironvine Capital Partners LLC, Ironvine Capital Partners LLC, Commerzbank Aktiengesellschaft FI, Exchange Traded Concepts LLC and Reilly Financial Advisors LLC. View Insider Buying and Selling for Xylem.

How do I buy shares of Xylem?

Shares of XYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xylem's stock price today?

One share of XYL stock can currently be purchased for approximately $82.10.

How big of a company is Xylem?

Xylem has a market capitalization of $14.78 billion and generates $5.21 billion in revenue each year. The industrial products company earns $549 million in net income (profit) each year or $2.88 on an earnings per share basis. Xylem employs 17,000 workers across the globe.View Additional Information About Xylem.

What is Xylem's official website?

The official website for Xylem is http://www.xyleminc.com/.

How can I contact Xylem?

Xylem's mailing address is 1 INTERNATIONAL DRIVE, RYE BROOK NY, 10573. The industrial products company can be reached via phone at 914-323-5700 or via email at [email protected]


MarketBeat Community Rating for Xylem (NYSE XYL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  454 (Vote Outperform)
Underperform Votes:  415 (Vote Underperform)
Total Votes:  869
MarketBeat's community ratings are surveys of what our community members think about Xylem and other stocks. Vote "Outperform" if you believe XYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XYL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel